Study of the Risk Factors and Complications of Diabetes Mellitus After Live Kidney Donation

Abuelmagd, Mohammed M; Nagib, Ayman Maher; Abu-Elmagd, Megahed; Refaie, Ayman; Elhindi, Y.A.; Ahmed, Mohammed; Ali, Mohamed I.; Bakr, Mohamed A.

doi:10.1016/j.transproceed.2014.11.064

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single‐center US study that included 3752 predominantly white donors (1975‐2014, 17% obese) found PDDM rates by the end of follow‐up in 12% vs 6% of donors with baseline BMI ≥30 vs <30 kg/m 2 , and adjusted risk related to obesity was three times that of normal weight . Another smaller single‐center study of 388 donors from Egypt (1976‐2014) also found increased PDDM risk with higher BMI (4.1% in normal weight, 6% in overweight, and 25% in obese donors over follow‐up to 2014) . The higher incidence of PDDM in these two single‐center cohorts likely reflects maximal follow‐up over decades.…”

Section: Discussionmentioning

confidence: 98%

Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records

Lentine

Koraishy

Sarabu

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

We examined a novel linkage of national US donor registry data with records from a pharmacy claims warehouse (2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016) to examine associations (adjusted hazard ratio, LCL aHR UCL ) of post-donation fills of antidiabetic medications (ADM, insulin or non-insulin agents) with body mass index (BMI) at donation and other demographic and clinical factors. In 28 515 living kidney donors (LKDs), incidence of ADM use at 9 years rose in a graded manner with higher baseline BMI: underweight, 0.9%; normal weight, 2.1%; overweight, 3.5%; obese, 8.5%. Obesity was associated with higher risk of ADM use compared with normal BMI (aHR, 3.36 4.59 6.27 ). Metformin was the most commonly used ADM and was filled more often by obese than by normal weight donors (9-year incidence, 6.87% vs 1.85%, aHR, 3.55 5.00 7.04 ). Insulin use was uncommon and did not differ significantly by BMI. Among a subgroup with BMI data at the 1-year post-donation anniversary (n = 19 528), compared with stable BMI, BMI increase >0.5 kg/m 2 by year 1 was associated with increased risk of subsequent ADM use (aHR, 1.03 1.48 2.14, P = .04). While this study did not assess the impact of donation on the development of obesity, these data support that among LKD, obesity is a strong correlate of ADM use.

show abstract

Section: Discussionmentioning

confidence: 98%